Ambrisentan/Tadalafil

安立生坦/他达拉非

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAmbrisentan/Tadalafil
Drug Alias NameTadalafil/Ambrisentan安立生坦+他达拉非他达拉非+安立生坦Tadalafil+Ambrisentan他达拉非/安立生坦 +[6] 
ClassificationSmall molecules
Mechanisms of ActionPhosphodiesterase 5A inhibitorsEndothelin receptor type A antagonists
TargetsEndothelin receptor type APhosphodiesterase 5A
Therapy Area/IndicationsHypertension, Pulmonary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsYes AmbrisentanTadalafil
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcHammersmith Medicines Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHammersmith Medicines ResearchGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsHypertension, Pulmonary

Other Information

ATC CodeN/A
Related LinksN/A